Researchers have created a novel Covid-19 vaccine called DIOSynVax that can be administered using air-jet technology rather than a needle. This revolutionary vaccine aims to provide long-lasting protection against not only SARS-CoV-2 but also other related diseases.
Traditionally, the body’s immune system can recognize and block the spike proteins used by the SARS virus to enter cells. However, the spike protein sequence of Covid-19 keeps changing with each variant, making it harder for the immune system to combat the virus effectively. In contrast, the National Institute for Health and Care Research’s (NIHR) Cambridge Clinical Research Facility has developed DIOSynVax without relying on a specific protein sequence. Instead, they have focused on predicting the virus’s potential evolution, identifying common elements across different strains, and employing synthetic gene technology using DNA.
Due to its design, DIOSynVax can be manufactured as a powder, allowing for wider distribution, including to countries without reliable cold-chain storage. This accessibility may help increase vaccine availability and reduce inequalities.
Given the uncertainty surrounding the most effective and enduring immune responses, it is crucial to test various vaccine technologies as part of the UK and global response to the pandemic. What makes the clinical trial even more exciting is its investigation of needle-free administration through the skin using a specialized device. This, combined with the stable DNA vaccine technology, has the potential to revolutionize mass vaccination efforts worldwide. The current trial represents a significant milestone in advancing this technology toward the development of a universal coronavirus vaccine.
